Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), announced today that ...

Scientists have created a new "molecular map" uncovering how an important human receptor involved in blood clotting and ...

Patients who have heart failure with preserved ejection fraction (HFpEF) and high blood pressure in the lungs (pulmonary ...

Clinical trial designed to evaluate ROC-101 in combination with standard of care therapies including sotatercept NATICK, Mass. /PRNewswire/ -- AllRock Bio, Inc., a ...

Scientists have created a new “molecular map” uncovering how an important human receptor involved in blood clotting and inflammation works—an advance that could help us design better drugs for ...

The Scottish Medicines Consortium said it had accepted five out of six newly-licensed medicines under consideration ...

Cardiology experts from UCSF Health presented new research and clinical findings at the American College of Cardiology’s (ACC) Annual Scientific Session and Expo in New Orleans, March 28 to 30. The ...

A recent study published in CHEST found that treatment-naïve adults with obesity-hypoventilation syndrome receiving a ...

A University of Alberta research team has found a genetic variant that can be used to identify which patients with pulmonary arterial hypertension need the most urgent care. "This could potentially ...

Guest writer Genesis “Gigi” Gonzalez says that, while living with PH, there are moments when she wants to ask, "Why did this ...